Pharmaceuticals

Dr. Lu Xianping, crowned EY Entrepreneur Of The Year, didn't just invent new drugs; he helped reinvent China's entire pharmaceutical industry.

As 10x Genomics preps for its J.P. Morgan spotlight, investors seek a clear path to profit amid fierce competition and groundbreaking innovation.

With CEO David Endicott set to present at the J.P. Morgan Healthcare Conference, all eyes are on Alcon's strategy for innovation and market growth.

Emmaus Life Sciences outsources its sickle cell drug Endari® in North America to focus on global growth, as NeoImmuneTech gains a key U.S. market foothold.

A 41-year-old mother's massive heart attack on Valentine's Day sparked a miraculous story of survival, advanced medicine, and profound gratitude.

As 'GLP-1 patch' ads flood social media for New Year's, an investigation reveals misleading marketing, a lack of science, and complex global companies.

The biopharma investment giant has now acquired 100% of the royalty stream for Roche's blockbuster SMA drug, a strategic move years in the making.

Oncodesign Precision Medicine and Navigo Proteins end their radiotheranostics pact, shifting focus to internal programs amid high-stakes R&D challenges.

The Danish firm scraps its 2025 revenue forecast, accepting a larger loss in a bold move to secure more lucrative future deals for its key drug candidates.

Biotech pioneer Dr. Patrick Soon-Shiong is named a top influencer in oncology, boosting ImmunityBio amid strong sales and a promising drug pipeline.

Genmab discontinues its 'encouraging' lung cancer drug, acasunlimab, in a bold strategic pivot to accelerate its most promising late-stage assets.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

With promising new drugs for obesity and liver disease, clinical-stage MetaVia steps into the spotlight at a key industry conference, facing giants and high hopes.

Azenta divests its medical refrigeration unit to streamline its portfolio, signaling a strategic pivot to its high-growth multiomics and sample management services.

With a promising schizophrenia drug stalled by FDA requirements and finances tight, Reviva Pharmaceuticals' upcoming presentation is more than just a talk.

A new partnership with logistics giant Uniphar will bring Zevra's breakthrough NPC therapy, MIPLYFFA, to patients in underserved regions worldwide.

After resolving a key manufacturing issue, Unicycive has resubmitted its kidney drug NDA, offering new hope for dialysis patients with a lower pill burden.

Adlai Nortye licenses its promising pan-RAS cancer inhibitor to ASK Pharm for Greater China in a deal valued at up to $230 million.

Diamyd Medical's pivotal Phase 3 trial gets a nine-month acceleration, raising hopes for a new precision therapy that preserves insulin production.

As pharma moves beyond small molecules, a new integrated platform helps developers navigate the challenges of PROTACs, peptides, and antibody drugs.